NEMAURA MEDICAL INC (NMRD) Stock Price, Quote, News and Overview
NASDAQ:NMRD - Nasdaq - US6404422080 - Common Stock - Currency: USD
NMRD Quote, Performance and Key Statistics
0.1053
-0.02 (-17.8%)
The current stock price of NMRD is 0.1053 USD. In the past month the price decreased by -54.22%. In the past year, price decreased by -94.2%.
NMRD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About NMRD
Company Profile
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The firm is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Company Info
NEMAURA MEDICAL INC
57 W 57th St
New York City NEW YORK 10019 US
CEO: Dewan Fazlul Hoque Chowdhury
Employees: 36
Company Website: https://nemauramedical.com/
NEMAURA MEDICAL INC / NMRD FAQ
What is the stock price of NEMAURA MEDICAL INC today?
The current stock price of NMRD is 0.1053 USD. The price decreased by -17.8% in the last trading session.
What is the ticker symbol for NEMAURA MEDICAL INC stock?
The exchange symbol of NEMAURA MEDICAL INC is NMRD and it is listed on the Nasdaq exchange.
On which exchange is NMRD stock listed?
NMRD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEMAURA MEDICAL INC stock?
7 analysts have analysed NMRD and the average price target is 8.67 USD. This implies a price increase of 8133.62% is expected in the next year compared to the current price of 0.1053. Check the NEMAURA MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEMAURA MEDICAL INC worth?
NEMAURA MEDICAL INC (NMRD) has a market capitalization of 3.04M USD. This makes NMRD a Nano Cap stock.
How many employees does NEMAURA MEDICAL INC have?
NEMAURA MEDICAL INC (NMRD) currently has 36 employees.
Is NEMAURA MEDICAL INC (NMRD) expected to grow?
The Revenue of NEMAURA MEDICAL INC (NMRD) is expected to grow by 43.63% in the next year. Check the estimates tab for more information on the NMRD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEMAURA MEDICAL INC (NMRD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NMRD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NMRD, evaluating the profitability, health, valuation and growth aspects
- NEMAURA MEDICAL INC (NMRD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEMAURA MEDICAL INC (NMRD) Sales and EPS estimates to see what analysts future expectations are.
- NEMAURA MEDICAL INC (NMRD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEMAURA MEDICAL INC (NMRD) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEMAURA MEDICAL INC (NMRD) Stock Chart to make your own analysis
- NEMAURA MEDICAL INC (NMRD) Latest news and press-releases to stay up to date.
Does NEMAURA MEDICAL INC (NMRD) stock pay dividends?
NMRD does not pay a dividend.
When does NEMAURA MEDICAL INC (NMRD) report earnings?
NEMAURA MEDICAL INC (NMRD) will report earnings on 2024-02-22, after the market close.
What is the Price/Earnings (PE) ratio of NEMAURA MEDICAL INC (NMRD)?
NEMAURA MEDICAL INC (NMRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
What is the Short Interest ratio of NEMAURA MEDICAL INC (NMRD) stock?
The outstanding short interest for NEMAURA MEDICAL INC (NMRD) is 0% of its float. Check the ownership tab for more information on the NMRD short interest.
NMRD Technical Analysis
NMRD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRD. Both the profitability and financial health of NMRD have multiple concerns.
NMRD Financial Highlights
Over the last trailing twelve months NMRD reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 39.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.35% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NMRD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NMRD. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 42.95% and a revenue growth 43.63% for NMRD